Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
Ribociclib and Bicalutamide in AR+ TNBC
- Conditions
- Interventions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Kari Wisinski
- Target Recruit Count
- 37
- Registration Number
- NCT03090165
- Locations
- 🇺🇸
Michigan State University, Lansing, Michigan, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Penn State Cancer Institute, Hershey, Pennsylvania, United States
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03081234
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT03078751
- Locations
- 🇺🇸
Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Northside Hospital Central Research Dept., Atlanta, Georgia, United States
🇺🇸Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Ronald Buckanovich
- Target Recruit Count
- 35
- Registration Number
- NCT03056833
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸UPMC Hillman Cancer Center Passavant (OHA), Pittsburgh, Pennsylvania, United States
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT03050398
- Locations
- 🇺🇸
PeaceHealth St Joseph Medical Center, Bellingham, Washington, United States
🇺🇸Arizona Oncology Associates PC HAL, Sedona, Arizona, United States
🇺🇸Oncology Speciialists of Charlotte, Charlotte, North Carolina, United States
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
- Conditions
- Locally Advanced AngiosarcomaLocally Advanced LeiomyosarcomaLocally Advanced Malignant Peripheral Nerve Sheath TumorMetastatic Epithelioid SarcomaMetastatic FibrosarcomaMetastatic Undifferentiated Pleomorphic SarcomaUnresectable LeiomyosarcomaLocally Advanced MyxofibrosarcomaMetastatic AngiosarcomaMyxofibrosarcoma
- Interventions
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT03009201
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
- Conditions
- Recurrent Endometrial CarcinomaStage IIIA Uterine Corpus Cancer AJCC v8Stage IVB Uterine Corpus Cancer AJCC v8Recurrent Endometrial Endometrioid AdenocarcinomaRefractory Endometrial CarcinomaRefractory Endometrial Endometrioid AdenocarcinomaStage IVA Uterine Corpus Cancer AJCC v8Stage III Uterine Corpus Cancer AJCC v8Stage IIIC Uterine Corpus Cancer AJCC v8Stage IIIC1 Uterine Corpus Cancer AJCC v8
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT03008408
- Locations
- 🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 241
- Registration Number
- NCT02974725
- Locations
- 🇸🇪
Novartis Investigative Site, Stockholm, Sweden
🇺🇸Uni of TX MD Anderson Cancer Cntr, Houston, Texas, United States
🇺🇸Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee, United States
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
- Conditions
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3246
- Registration Number
- NCT02941926
- Locations
- 🇺🇸
Ventura County Hematology and Oncology, Oxnard, California, United States
🇺🇸Mid Florida Hematology and Onc Ctr, Orange, Florida, United States
🇺🇸Hope Cancer Center of East Texas, Tyler, Texas, United States
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
- Conditions
- Interventions
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Nader Sanai
- Target Recruit Count
- 48
- Registration Number
- NCT02933736
- Locations
- 🇺🇸
Barrow Brain and Spine, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.